Zobacz wszystkie

Eckert & Ziegler BEBIG: Eckert & Ziegler BEBIG: First Half-Year Results 2014 Published

2014-08-05 07:46:00
Ticker Giełda ISIC Kraj Miasto
EZBG XBRU Belgium Seneffe

Seneffe - Belgium, August 5th, 2014, Eckert & Ziegler BEBIG (Euronext: EZBG;

Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today the publication of its

report on the first half-year results 2014. The report including a selection of

consolidated key figures for the six months ending June 30th, 2014 can be

downloaded at:

www.bebig.eu > Investor Relations > Financial Reports

Eckert & Ziegler BEBIG

...Contributing to saving lives!

Eckert & Ziegler BEBIG, incorporated in 1996, is a European-based company active

in the medical device segment of the health care industry.

Eckert & Ziegler BEBIG's core business is the treatment of cancer using

brachytherapy, a special form of radiation therapy.

Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company

headquarters are in Belgium, with a production facility in both Germany and the

USA and subsidiaries throughout Europe as well as in India and Brazil. In

addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and

agents to support the international marketing of its product line.

The company's products and equipment are intended for use by oncologists,

radiologists, urologists, and medical physicists. Eckert & Ziegler BEBIG employs

more than 200 people. The company has been listed on the NYSE Euronext Brussels

stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg:



Eckert & Ziegler BEBIG s.a.

Investor Relations

Tel.: +32 (0) 64 520 808

E-mail: ir@bebig.eu

This announcement is distributed by GlobeNewswire on behalf of

GlobeNewswire clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and

other applicable laws; and

(ii) they are solely responsible for the content, accuracy and

originality of the information contained therein.

Source: Eckert & Ziegler BEBIG via GlobeNewswire